Structure and function of small arteries in salt-induced hypertension: Effects of chronic endothelin-subtype-A-receptor blockade

Hypertension

Volumn 30, Issue 4, 1997, Pages 905-911

  D'Uscio, Livius V ^c   Barton, Matthias ^c   Shaw, Sidney ^a   Moreau, Pierre ^c   Lüscher, Thomas F ^b  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c NONE

Author keywords

Basilar artery; Endothelin receptors; Endothelium derived relaxing factor; Mesenteric resistance artery; Rats, Dahl; Vascular remodeling

Indexed keywords

DARUSENTAN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BASILAR ARTERY; CONTROLLED STUDY; DRUG EFFECT; HYPERTENSION; MALE; MESENTERIC ARTERY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SALT INTAKE;

EID: 0030767296     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.4.905     Document Type: Article

References (38)

1. Dahl LK, Heine M, Tassinair L. Effects of chronic excess salt ingestion: evidence that genetic factors play an important role in susceptibility to experimental hypertension. J Exp Med. 1962;115: 1173-1190.
2. Rapp JP. Dahl salt-susceptible and salt-resistant rats. Hypertension. 1982;4:753-763.
3. Heistad DD, Baumbach GL. Cerebral vascular changes during chronic hypertension: good guys and bad guys. J Hypertens. 1992; 10(suppl 7):S71-S75.
4. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension: dual processes of remodeling and growth. Hypertension. 1993;21:391-397.
5. Baumbach GL, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertension. 1989;13:968-972.
6. Mulvany JM, Baumbach GL, Aalkjaer C, Heagerty AM, Korsgaard N, Schiffrin E, Heistad DD. Vascular remodeling. Hypertension. 1996;28:505-506. Letter.
7. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
8. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
9. Lüscher TF, Vanhoutte PM. The Endothelium: Modulator of Cardiovascular Function. Boca Raton, Fla: CRC Press: 1990;1-115.
10. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin Invest. 1989;83:1774-1777.
11. Dubey RK, Jackson EK, Lüscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell: role of cyclic-nucleotides and angiotensin 1 receptors. J Clin Invest. 1995; 96:141-149.
12. Moreau P, Takase H, Küng CF, van Rooijen M-M, Schaffner T, Lüscher TF. Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition. Stroke. 1995;26:1922-1929.
13. Deng LY, Thibault G, Schiffrin EL. Effect of hypertension induced by chronic nitric oxide synthase inhibition of structure and function of resistance arteries in the rat. Clin Exp Hypertens. 1993;15: 527-537.
14. Lee RMKW, Triggle CR. Morphometric study of mesenteric arteries from genetically hypertensive Dahl strain rats. Blood Vessels. 1986;23:199-224.
15. Lüscher TF, Raij L, Vanhoutte PM. Endothelium-derived vascular responses in normotensive and hypertensive Dahl rats. Hypertension. 1987;9:157-163.
16. Hiruta Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989; 78:225-228.
17. Duhin D, Pratt RK, Cooke JP, Dzau VJ. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vasc Med Biol. 1989;1:13-17.
18. Takase H, Moreau P, Lüscher TF. Endothelin receptor subtypes in small arteries: studies with FR139317 and bosentan. Hypertension. 1995;25:739-743.
19. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730-732.
20. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348: 732-735.
21. Warner TD, Allcock GH, Corder R, Vane JR. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol. 1993;110:777-782.
22. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J. Clin Invest. 1990;85:587-590.
23. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994;24:183-188.
24. Doucet J, Gonzalez W, Michel JB. Endothelin antagonists in salt-dependent hypertension associated with renal insufficiency. J Cardiovasc Pharmacol. 1996;27:643-651.
25. Munter K, Hergenröder S, Unger L, Kirchengast M. Oral treatment with an ETA-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm Pharmacol Lett. 1996; 6;90-92.
26. Raschack M, Unger L, Riechers H, Klinge D. Receptor selectivity of endothelin antagonists and prevention of vasoconstriction and endothelin-induced sudden death. J Cardiovasc Pharmacol. 1995; 26(suppl 3):S397-S399.
27. d'Uscio LV, Moreau P, Shaw S, Takase H, Barton M, Lüscher TF. Effects of chronic ET-A receptor blockade in angiotensin II-induced hypertension. Hypertension. 1997;29:435-441.
28. Chillon J-M, Heistad DD, Baumbach GL. Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension. 1996;27:794-798.
29. Wallenstein S, Zucker CL, Fleiss J. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.
30. Falloon BJ, Heagerty AM. In vitro perfusion studies of human resistance artery function in essential hypertension. Hypertension. 1994;24:16-23.
31. Rapp JP, McPartland RP, Sustarsic DL. A qualitative difference in plasma renin activity in Dahl rats susceptible or resistant to salt induced hypertension. Bochem Genet. 1980;18:1087-1096.
32. Sugimoto K, Gotoh E, Takasaki I, Ebina T, Iwamoto T, Takizawa T, Shionoiri H, Ishii M. AT1 receptor antagonist, TCV116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats. Clin Exp Pharmacol Physiol. 1996;23:282-286.
33. Larivière R, Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 1993;21:916-920.
34. Larivière R, Sventek P, Thibault G, Schiffrin EL. Endothelin-1 expression in blood vessels of DOCA-salt hypertensive rats treated with the combined ETA/ETB endothelin receptor antagonist bosentan. Can J Physiol Pharmacol. 1995;73:390-398.
35. Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dcpendent protein phosphorylation. Nature. 1983;306:174-176.
36. Nakashima M, Vanhoutte PM. Endothelin-1 and -3 cause endothelium-dependent hyperpolarization in the rat mesenteric artery. Am J Physiol. 1993;265:H2137-H2141.
37. Dohi Y, Criscione L, Pfeiffer K, Lüscher TF. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused SUR mesenteric resistance arteries. J Cardiovasc Pharmacol. 1994;24:372-379.
38. Kong J-Q, Taylor D, Fleming WW. Sustained hypertension in Dahl rats: negative correlation of agonist response to blood pressure. Hypertension. 1995;25:139-145.